1. Drug-Based Gold Nanoparticles Overgrowth for Enhanced SPR Biosensing of Doxycycline
   Syed Akif Raza Kazmi et al, 2020, Biosensors CrossRef
2. Post-Translational Modifications of Deubiquitinating Enzymes: Expanding the Ubiquitin Code
   Yanfeng Wang et al, 2021, Frontiers in Pharmacology CrossRef
3. Targeting myeloid-derived suppressor cells to attenuate vasculogenic mimicry and synergistically enhance the anti-tumor effect of PD-1 inhibitor
   Yinan Li et al, 2021, iScience CrossRef
4. Long noncoding RNA HULC regulates the NF‐κB pathway and represents a promising prognostic biomarker in liver cancer
   Shihai Liu et al, 2023, Cancer Medicine CrossRef
5. Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells
   Yuan Qin et al, 2015, Oncotarget CrossRef
6. New application of an old drug: Antitumor activity and mechanisms of doxycycline in small cell lung cancer
   SHENG-QI WANG et al, 2016, International Journal of Oncology CrossRef
7. Putative role of SUMOylation in controlling the activity of deubiquitinating enzymes in cancer
   Katarzyna C Masoumi et al, 2016, Future Oncology CrossRef
8. A novel inducible lentiviral system for multi-gene expression with human HSP70 promoter and tetracycline-induced promoter
   Shun Li et al, 2017, Applied Microbiology and Biotechnology CrossRef
9. Toward Tightly Tuned Gene Expression Following Lentiviral Vector Transduction
   Audrey Page et al, 2020, Viruses CrossRef
10. Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment
    Mei-Ling Huang et al, 2022, World Journal of Clinical Cases CrossRef
11. Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
    Chiara Varamo et al, 2019, Cancers CrossRef
12. RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer
    Sakib Haque et al, 2021, Pharmaceutics CrossRef